Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Stephen S. Chung
Selinexor, a First-In-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients With Myelodysplastic Syndromes Refractory to Hypomethylating Agents
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Related publications
Expanded Safety Analysis of Pevonedistat, a First-In-Class NEDD8-activating Enzyme Inhibitor, in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Blood Cancer Journal
Oncology
Hematology
Preclinical Activity of Selinexor, an Inhibitor of XPO1, in Sarcoma
Oncotarget
Oncology
Hypomethylating Agents in Combination With Histone Deacetylase Inhibitors in Higher Risk Myelodysplastic Syndromes: Is There a Light at the End of the Tunnel?
Cancer
Cancer Research
Oncology
Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes
Seminars in Oncology
Oncology
Hematology
Transplantation for Myelodysplastic Syndrome in the Era of Hypomethylating Agents
Current Opinion in Hematology
Hematology
A Novel Clofarabine Bridge Strategy Facilitates Allogeneic Transplantation in Patients With Relapsed/Refractory Leukemia and High-Risk Myelodysplastic Syndromes
Bone Marrow Transplantation
Transplantation
Hematology
Hematologic Responses to Deferasirox Therapy in Transfusion-Dependent Patients With Myelodysplastic Syndromes
Haematologica
Hematology
Landscape of Genetic Lesions in 944 Patients With Myelodysplastic Syndromes
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Improving Prognostic Tools for Patients With Myelodysplastic Syndromes
Mayo Clinic Proceedings
Medicine
